CERo Therapeutics Holdings, Inc.(CERO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CERO CERo Therapeutics Holdings, Inc.

Trading 01-20 15:33:00 EST Delay

{"stockData":{"symbol":"CERO","market":"US","secType":"STK","nameCN":"CERo Therapeutics Holdings, Inc.","latestPrice":0.041,"timestamp":1768941180000,"preClose":0.0401,"halted":0,"volume":66501,"delay":15,"changeRate":0.02244389027431434,"floatShares":1762500,"shares":21102700,"eps":-98.705194,"marketStatus":"Trading","change":0.0009,"latestTime":"01-20 15:33:00 EST Delay","open":0.0401,"high":0.044,"low":0.037,"amount":2759.5040161770003,"amplitude":0.174564,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-98.705194,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1768942800000},"marketStatusCode":2,"adr":0,"exchange":"OTCQB","adjPreClose":0.0401,"volumeRatio":0.087841},"requestUrl":"/m/hq/s/CERO","defaultTab":"news","newsList":[{"id":"2601093468","title":"Cero Therapeutics Reports Positive Safety Data in Phase 1 AML Trial of CER-1236","url":"https://stock-news.laohu8.com/highlight/detail?id=2601093468","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601093468?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:09","pubTimestamp":1767794950,"startTime":"0","endTime":"0","summary":"CERo Therapeutics Holdings Inc. has announced a clinical update from its ongoing Phase 1 CertainT-1 trial, evaluating CER-1236 in patients with acute myeloid leukemia . The company reported that, following the completion of the dose-limiting toxicity observation period for the first cohort, no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or treatment-related adverse events have been observed to date. In one patient with myelodysplastic syndrome progressing to AML, a 61-day platelet transfusion-free interval was noted after CER-1236 treatment, exceeding commonly referenced clinical benchmarks. Additional clinical details and progress were scheduled to be discussed during an analyst call on January 7, 2026. Results from the study have been presented in this update, with further data expected as the trial progresses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL5t1xzn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","SG9999014021.USD","BK4112","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","SG9999014013.SGD","SG9999014039.USD","IE00B64PRP62.GBP","CERO","IE00BKPKM429.USD","BK4139","BK4585","SG9999014005.SGD"],"gpt_icon":0},{"id":"2601809303","title":"Cero Therapeutics Holdings Inc - No Adverse Events Reported in First Cohort of Certaint-1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601809303","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601809303?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:09","pubTimestamp":1767794940,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA2D5BWW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2601180987","title":"Cero Therapeutics Provides Clinical Update on Phase 1  Trial of Cer-1236 in Aml (Certaint-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient With Myelodysplastic Syndrome/Aml","url":"https://stock-news.laohu8.com/highlight/detail?id=2601180987","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601180987?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:09","pubTimestamp":1767794940,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA2D5BWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2592902551","title":"Cero Therapeutics Holdings Inc. held special shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902551","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592902551?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:49","pubTimestamp":1766180986,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. held a special meeting of stockholders on December 19, 2025. Stockholders approved an amendment to the company's certificate of incorporation to authorize a reverse stock split at a ratio to be determined by the Board of Directors within a specified range. An amendment to the 2024 Equity Incentive Plan to increase the number of shares available for issuance was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the info","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL8ZYK9y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2592990414","title":"BRIEF-Cero Therapeutics Provides Clinical Update On Phase 1 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990414","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990414?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:09","pubTimestamp":1765976953,"startTime":"0","endTime":"0","summary":"BRIEF-Cero Therapeutics Provides Clinical Update On Phase 1 Clinical Trial Dec 17 (Reuters) - CERo Therapeutics Holdings Inc CERO.PK:CERO THERAPEUTICS PROVIDES CLINICAL UPDATE ON PHASE 1 CLINICAL TRIA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XM12S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2592909619","title":"Cero Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of Cer-1236 in Aml (Certaint-1)","url":"https://stock-news.laohu8.com/highlight/detail?id=2592909619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592909619?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:01","pubTimestamp":1765976513,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XM12S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2592990982","title":"Cero Therapeutics Advances Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990982","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990982?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976433,"startTime":"0","endTime":"0","summary":"CERo Therapeutics Holdings Inc. has provided a clinical update on its ongoing Phase 1 clinical trial of CER-1236, an investigational cellular immunotherapy for patients with acute myeloid leukemia . The trial, known as CertainT-1, has completed the dose-limiting toxicity  observation period for the first patient in the second cohort, who received a dose level of 4e6 cells/kg, four times higher than the dose administered to the first cohort. Additionally, a second patient in the first cohort has received a fourth additional dose and remains on study. The Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in various AML patient populations. Results from the study have not yet been presented, and enrollment and dosing are ongoing with continued safety monitoring.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLjbGkl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0314104364.USD","LU2095319765.USD","BK4139","SG9999014005.SGD","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","NDAQ","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014013.SGD","LU2210150020.SGD","CERO","SG9999014021.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2588055715","title":"BRIEF-Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-List","url":"https://stock-news.laohu8.com/highlight/detail?id=2588055715","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588055715?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:36","pubTimestamp":1764682577,"startTime":"0","endTime":"0","summary":"BRIEF-Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-ListDec 2 (Reuters) - CERo Therapeutics Holdings Inc CERO.PK:CERO THERAPEUTICS HOLDINGS INC - CONTINUES TO EVALUA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X8025:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2588055731","title":"Cero Therapeutics Announces $14.6 Million Private Stock Sale to Institutional Investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2588055731","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588055731?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:31","pubTimestamp":1764682266,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. has entered into a new purchase agreement with an institutional investor, allowing the company to issue and sell up to approximately $14.6 million of its common stock. This agreement is a continuation of the company's previous equity line arrangements, which have raised proceeds through the sale of shares under agreements dated February 2024, November 2024, and July 2025. Under the new agreement, Cero Therapeutics may direct the investor to purchase shares at specified times and prices, subject to certain limitations, with each purchase not exceeding 10,000 shares or $100,000 per transaction. The sales are being made in a private placement without registration under the Securities Act.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL1Rsd81:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2588058622","title":"Cero Therapeutics Holdings Inc - Continues to Evaluate Additional Options for up-List","url":"https://stock-news.laohu8.com/highlight/detail?id=2588058622","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588058622?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:31","pubTimestamp":1764678662,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X8025:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2584952450","title":"CERo Therapeutics Cut to Hold From Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584952450","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584952450?lang=en_us&edition=fundamental","pubTime":"2025-11-19 01:36","pubTimestamp":1763487360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CERO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 12:36 ET (17:36 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4139","BK4539","CERO"],"gpt_icon":0},{"id":"2584647909","title":"Cero Therapeutics Holdings Inc. Announces Date for 2025 Special Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2584647909","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584647909?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:30","pubTimestamp":1763379057,"startTime":"0","endTime":"0","summary":"CERo Therapeutics Holdings Inc. has announced that it will hold a Special Meeting of Stockholders in 2025. The meeting has been called for purposes set forth in the official meeting notice. The Board has also noted that the persons named in the proxy card will have discretionary authority to vote on any additional matters that may properly come before the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDLS8dw4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2581272657","title":"CERo Therapeutics Advances Phase 1 AML Trial with Higher Dosing of CER-1236","url":"https://stock-news.laohu8.com/highlight/detail?id=2581272657","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581272657?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:00","pubTimestamp":1762347632,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. has announced the initiation of the second cohort in its Phase 1 clinical trial evaluating CER-1236 in patients with acute myeloid leukemia . According to the company, the first patient in this new cohort received an initial dose of CER-1236 at twice the amount given to patients in the first cohort, followed by a second identical dose 48 hours later. The company reported that no dose limiting toxicity has been observed to date, allowing for an increase in dosing for this cohort. The safety data and cell expansion results observed thus far are guiding the determination of a Phase 2 dose. Results from the ongoing study will be shared as they become available.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL1hL4pV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","BK4588","CERO","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4585","BK4139","IE00B64PRP62.GBP","NDAQ","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2580348730","title":"Cero Therapeutics Presents Promising Phase 1 Data for Lead Immunotherapy CER-1236 in AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2580348730","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580348730?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:05","pubTimestamp":1762265126,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDLcdFXKg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU0314104364.USD","CERO","BK4585","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4588","LU2210149790.SGD","BK4139","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112"],"gpt_icon":0},{"id":"2580215587","title":"Cero Therapeutics announces listing on OTC Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2580215587","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580215587?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:05","pubTimestamp":1762175117,"startTime":"0","endTime":"0","summary":"CERo Therapeutics (CERO) announces its shares continue to be listed on the public markets under the ticker symbol CERO. Effective as of market open...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-announces-listing-on-otc-markets-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-announces-listing-on-otc-markets-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CERO","LENZ","BK4007","BK4539"],"gpt_icon":0},{"id":"2579624155","title":"Cero Therapeutics discloses Nasdaq Panel listing determination","url":"https://stock-news.laohu8.com/highlight/detail?id=2579624155","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579624155?lang=en_us&edition=fundamental","pubTime":"2025-10-30 07:35","pubTimestamp":1761780916,"startTime":"0","endTime":"0","summary":"CERo Therapeutics (CERO) “announced the receipt of the determination of the Nasdaq Hearings Panel to deny the Company’s request to continue the lis...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-discloses-nasdaq-panel-listing-determination-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-discloses-nasdaq-panel-listing-determination-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539",".IXIC","SQQQ","TSYW.SI","QID","USJW.SI","PSQ","USAW.SI","BK4139","NQmain","CERO","NVIW.SI","LENZ","TQQQ","BK4007","MNQmain","QLD"],"gpt_icon":0},{"id":"2579153234","title":"Cero Therapeutics Shares to Be Suspended from Nasdaq Trading October 31","url":"https://stock-news.laohu8.com/highlight/detail?id=2579153234","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579153234?lang=en_us&edition=fundamental","pubTime":"2025-10-30 07:23","pubTimestamp":1761780187,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. has announced that trading of its common stock on the Nasdaq will be suspended at the open of trading on October 31, following a determination by the Nasdaq Hearings Panel. The company is appealing the decision and exploring trading on the OTC Markets.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on October 29, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL561w8W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","BK4588","CERO","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4585","BK4139","IE00B64PRP62.GBP","NDAQ","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2577684820","title":"CERo Therapeutics Advances Phase 1 Trial of CER-1236 in AML with Third Patient Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2577684820","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577684820?lang=en_us&edition=fundamental","pubTime":"2025-10-21 20:15","pubTimestamp":1761048937,"startTime":"0","endTime":"0","summary":"CERo Therapeutics Holdings Inc. announced that investigators have been authorized to administer a third infusion of its investigational cell therapy, CER-1236, to a patient enrolled in the first cohort of its ongoing Phase 1 clinical trial for acute myeloid leukemia . The third dose, identical in amount to the previous two infusions, is intended to provide additional safety and dosing data to evaluate a multi-dose administration strategy. The results of the study have not yet been presented. CERo also completed the first tranche of a planned $7 million financing, which is expected to extend its cash runway and support continued clinical development as well as compliance with Nasdaq listing requirements. The first dosing of a patient in the second cohort of the trial is anticipated in the coming weeks, pending regulatory approvals.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL3NKfBv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4585","BK4588","CERO","NDAQ","LU0314104364.USD","BK4139","IE00B64PRP62.GBP","BK4112","LU2210149790.SGD"],"gpt_icon":0},{"id":"2577205568","title":"Cero Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of Cer-1236 in Aml","url":"https://stock-news.laohu8.com/highlight/detail?id=2577205568","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577205568?lang=en_us&edition=fundamental","pubTime":"2025-10-21 20:15","pubTimestamp":1761048900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nTUA5GNF2F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2575775531","title":"CERo Therapeutics Holdings (CERO) Receives a Buy from Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2575775531","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575775531?lang=en_us&edition=fundamental","pubTime":"2025-10-16 02:55","pubTimestamp":1760554530,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Jason McCarthy maintained a Buy rating on CERo Therapeutics Holdings yesterday. The company’s shares opened today at $2.87. McC...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cero-therapeutics-holdings-cero-receives-a-buy-from-maxim-group-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cero-therapeutics-holdings-cero-receives-a-buy-from-maxim-group-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CERO","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cero.bio","description":"CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.","exchange":"OTCQB","name":"CERo Therapeutics Holdings, Inc.","nameEN":"CERo Therapeutics Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CERo Therapeutics Holdings, Inc.(CERO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CERo Therapeutics Holdings, Inc.(CERO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CERo Therapeutics Holdings, Inc.,CERO,CERo Therapeutics Holdings, Inc.股票,CERo Therapeutics Holdings, Inc.股票老虎,CERo Therapeutics Holdings, Inc.股票老虎国际,CERo Therapeutics Holdings, Inc.行情,CERo Therapeutics Holdings, Inc.股票行情,CERo Therapeutics Holdings, Inc.股价,CERo Therapeutics Holdings, Inc.股市,CERo Therapeutics Holdings, Inc.股票价格,CERo Therapeutics Holdings, Inc.股票交易,CERo Therapeutics Holdings, Inc.股票购买,CERo Therapeutics Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CERo Therapeutics Holdings, Inc.(CERO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CERo Therapeutics Holdings, Inc.(CERO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}